Starlight Therapeutics

We are thrilled to announce?Inaugural Members of Scientific Advisory Board of Starlight Therapeutics, marking a major milestone in our commitment to advancing therapies for brain and CNS cancers. We’re honored to be joined by four extraordinary leaders in neuro-oncology: ??Dr. Mitchel S. Berger, M.D. : Chair of the UCSF Department of Neurological Surgery, director of the Brain Tumor Center, Director of Center for Neurological Injury and Repair and, co-director of Adult Brain Tumor Surgery Program at University of California, San Francisco . ??Dr. Lisa M. DeAngelis, M.D. : Chief Physician Executive and Scott M. and Lisa G. Stuart Chair at Memorial Sloan Kettering Cancer Center -oversees all clinical services, research, medical education, and multi-center collaborations, including the 500-bed Memorial Hospital, 13 outpatient facilities, and seven regional care sites across NY and NJ. ??Dr. Stuart Grossman, M.D. : Professor of Oncology at the Johns Hopkins Kimmel Cancer Center, is co-Leader of the Brain Cancer Program and has directed the clinical and research neuro-oncology efforts at Johns Hopkins Medicine since 1981. ??Dr. John Laterra, MD, Ph.D. : is a Professor of Neurology, Oncology and Neuroscience and Co-Director of the Brain Cancer Disease Group at the Johns Hopkins Kimmel Cancer Center. We look forward to the impactful insights they’ll bring to shape the future of our lead candidate, STAR-001. A special congratulations to Drs. Berger and Grossman on receiving the prestigious Lifetime Achievement Award from the Society for Neuro-Oncology Stay tuned as we harness the expertise of this esteemed board to drive innovation in cancer treatment. Read the full PR : https://bit.ly/3YBUHKw Learn more about Starlight Therapeutics: starlightthera.com

Today, February 4th, is #WorldCancerDay. According to worldcancerday.org, world cancer day is an international day observed every 4th of February?to raise awareness about cancer, encourage its prevention, and mobilize action to address the global cancer epidemic. We wanted to take a moment to share our commitment to making a meaningful impact on patients fighting? #cancer globally. At Lantern Pharma Inc. (Nasdaq: LTRN), we firmly believe that novel cancer drugs should be accessible and affordable for everyone. We are innovating novel cancer drugs using #artificialintelligence and? #machinelearning to deliver precision oncology therapies to cancer patients with significantly reduced costs and timelines. ??Learn more about World Cancer Day - www.worldcancerday.org ??Learn more about how we are transforming cost, pace, and timeline of? #oncology drug development www.lanternpharma.com #CancerAwareness #WCD2025 #PrecisionOncology #Research

Great News Lantern Pharma Inc. (Nasdaq: LTRN)!!

?? Starlight SAB Highlight 04.Meet?Dr. John Laterra, M.D., Ph.D. ! We are excited to feature Dr. John Laterra, Professor of Neurology, Oncology, and Neuroscience and Co-Director of the Brain Cancer Disease Group at the Johns Hopkins Medicine / Johns Hopkins Kimmel Cancer Center, as a valued member of Starlight Therapeutics’ Scientific Advisory Board. Dr. Laterra is internationally acclaimed for his research on tumor vascular biology, mechanisms of brain tumor malignancy, and identifying new therapeutic targets for gliomas. His clinical expertise, combined with research funded by the NIH and private foundations, has led to innovative approaches in diagnosing and treating primary brain tumors and cancer-related neurological complications. We are honored to have his profound insights and leadership as we advance STAR-001 and work toward transforming the future of brain and CNS cancer treatment. Learn more about Dr. Laterra: https://lnkd.in/dEai7s-4 Read the full release: https://bit.ly/3YBUHKw Visit our website: https://starlightthera.com #NeuroOncology #BrainCancer #Innovation #StarlightTherapeutics

??Starlight SAB Highlight 03. Meet Dr. Stuart Grossman M.D.! Next in our series highlighting the esteemed members of Starlight Therapeutics’ Scientific Advisory Board is Dr. Stuart Grossman, Professor of Oncology at the Johns Hopkins Medicine - Johns Hopkins Kimmel Cancer Center. Dr. Grossman has dedicated over four decades to advancing clinical and translational brain cancer research. He has served as Principal Investigator and Director of the Central Operations office of the National Cancer Institute (NCI)-funded Phase I/II brain tumor consortia (New Approaches to Brain Tumor Therapy CNS Consortium and the Adult Brain Tumor Consortium) for the past 22 years. His leadership in multidisciplinary clinical trials has profoundly shaped the field, providing hope to patients and families affected by brain cancers. We are deeply grateful to have access to his unparalleled knowledge and leadership as we push forward the development of STAR-001 and our mission to transform treatment for brain and CNS cancers. Stay tuned as we introduce more exceptional members of our SAB! Learn more about Dr. Grossman: https://lnkd.in/dM3Wu6km Read the full release: https://bit.ly/3YBUHKw Visit our website: https://starlightthera.com #NeuroOncology #BrainCancer #Innovation #StarlightTherapeutics

?? Starlight SAB Highlight 02. Meet Dr. Lisa M. DeAngelis, M.D! We’re proud to introduce inaugural member of Starlight Therapeutics’ Scientific Advisory Board - Dr. Lisa M. DeAngelis, M.D! Dr. DeAngelis is the Chief Physician Executive and Scott M. and Lisa G. Stuart Chair at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. DeAngelis oversees all clinical services, research, medical education, and multi-center collaborations, including the 500-bed Memorial Hospital, 13 outpatient facilities, and seven regional care sites across NY and NJ. Dr. DeAngelis is an internationally recognized leader in brain cancer research and treatment. With over 350 peer-reviewed publications and a legacy of clinical leadership, Dr. DeAngelis served as chair of the Department of Neurology MSKCC from 1997 to 2018, and co-founded MSK’s Brain Tumor Center. Dr. DeAngelis is an elected member of National Academy of Medicine, fellow and former Vice Chair of American Neurological Association (ANA) and fellow of American Academy of Neurology (AAN), which in 2019 awarded her the organization’s highest honor, the Wartenberg Lecture. Her exceptional contributions exemplify the excellence that will guide Starlight’s development of groundbreaking treatments for CNS cancer patients, starting from STAR-001. We are honored to have the opportunity to draw upon her profound expertise and leadership. Stay tuned as we continue to highlight each member of our exceptional SAB. Learn more about Dr. DeAngelis : https://lnkd.in/eEs3UvZm Read the full release: https://bit.ly/3YBUHKw Visit our website: https://starlightthera.com

?? Starlight SAB Highlight 01. Meet Dr. Mitchel S. Berger, M.D. ! We’re proud to introduce inaugural member of Starlight Therapeutics’ Scientific Advisory Board - Dr. Mitchel S. Berger! Dr. Berger is the Chair of the Department of Neurosurgery and Director of the Brain Tumor Center at University of California, San Francisco, where he is a national leader in treating complex brain and spinal cord tumors. Renowned for his pioneering work in brain mapping, Dr. Berger is a nationally recognized expert in treating brain and spinal cord tumors and tumor-related epilepsy in adults and children. Dr. Berger has completed American Cancer Society fellowships in neuro-oncology at UCSF, research fellowship by the Brain Tumor Research Center, and in pediatric neurosurgery at the The Hospital for Sick Children Children at University of Toronto. Dr. Berger was elected to American Association of Neurological Surgeons (AANS) Surgeons' board of directors and appointed to American Board of Neurological Surgery. Dr. Berger’s dedication to advancing neuro-oncology reflects the very essence of Starlight’s mission to pioneer breakthroughs in brain and CNS cancer treatment. We’re honored to have his expertise guiding the development of our lead drug candidate, STAR-001, and beyond! Stay tuned as we continue to highlight each member of our exceptional SAB. Learn more about Dr. Berger : https://lnkd.in/ebbH7zXg Read the full release: https://bit.ly/3YBUHKw Visit our website: https://starlightthera.com #NeuroOncology #BrainCancer #MedicalInnovation

??? Check out this KOL Webinar! https://lnkd.in/eMBCcFEf During 2022 Brain Tumor Awareness Month, Lantern Pharma hosted a key opinion leader (KOL) webinar focusing on glioblastoma multiforme (GBM) and the potential of Lantern’s drug candidate LP-184(STAR-001) for GBM as well as other brain cancers, featuring Dr. John Laterra and Dr. Holdhoff Matthias of Johns Hopkins Medicine. Brain Tumor Awareness month, which is also known as “Gray May”, is the month that is meant to bring support and awareness to the estimated 700,000 people in the US living with primary brain tumors and to their families and caregivers. #GBM is one of the most common types of primary brain tumors with an estimated 13,000 people in the US diagnosed each year. Patients with GBM have a very poor prognosis - and it is in part due to the lack of effective new therapies that can cross the blood brain barrier (BBB) and there is an urgent and unmet clinical need for new therapies. Starlight therapeutic is working towards finding better treatment options for GBM patients, starting from our drug candidate, STAR-001. Lantern Pharma Inc. (Nasdaq: LTRN) is currently enrolling patients for phase 1 clinical trial of STAR-001 (LP-184) in solid tumors and GBM.?

#Glioblastoma (#GBM) is the most common malignant primary brain tumor accounting for approximately 50% cases of all gliomas. It is the most aggressive form of glioma with a 5-year survival rate as low as 5%. An estimated 240,000 new cases worldwide and 13,000 in the USA are diagnosed with GBM each year. Starlight therapeutic is working towards finding better treatment options for GBM patients, starting from our drug candidate, STAR-001. Lantern Pharma Inc. (Nasdaq: LTRN) is currently enrolling patients for phase 1 clinical trial of STAR-001 (LP-184) in solid tumors and GBM. Watch the full webinar to learn more https://lnkd.in/eiNTbM46 Learn more about STAR-001 and Starlight Therapeutics starlightthera.com

?? Exciting News for STAR-001 Yesterday, Lantern Pharma Inc. (Nasdaq: LTRN) announced that our Investigational Drug-Candidate, STAR-001 (LP-184), Received Fast-Track Designation in #Glioblastoma from the #FDA LP-184, which will be developed as STAR-001 for CNS and other neuro-oncology indications by Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma, has the potential to be the first new drug for treating GBM in more than 20 years. Read the full release: https://bit.ly/3YmdfQ2 Visit our website: www.starlightthera.com Visit Lantern Pharma's website: www.lanternpharma.com